Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1645 1653 1654 1674
This examiner grants 58% of resolved cases
Amanda Mary Zahorik has 83 resolved cases in Art Unit 1635 of Technology Center 1600. The allowance rate is 57.8 percent. The interview lift is 49.0 percent, and the median days to allowance is 1317. The interview lift of 49.0 percent is a key metric for this examiner, suggesting that direct communication is effective. With 83 cases resolved, the 57.8 percent allowance rate indicates the examination environment.
The 1317-day median pendency is the duration for the 1600 technology center. Practitioners should prioritize interviews to take advantage of the 49.0 percent lift, which can improve the odds of a grant. The 57.8 percent allowance rate serves as a baseline that is enhanced by verbal advocacy. The 1317-day timeline provides a benchmark for the duration of prosecution in this art unit. These figures allow for a strategic approach to patent acquisition.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18557218 | LIPID NANOMATERIALS AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18572654 | METHODS OF DETERMINING RESPONSIVENESS TO CHEMOTHERAPEUTIC COMPOUNDS FOR CANCER THERAPY | Non-Final OA | President and Fellows of Harvard College |
| 18488316 | HSD17B13 VARIANTS AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18674830 | DEVICES, SYSTEMS, KITS, AND METHODS FOR ON-FARM DETECTION OF CONTAMINATION | Non-Final OA | Purdue Research Foundation |
| 18667652 | NON-INVASIVE SITE-SPECIFIC MEASUREMENT OF TRANSGENE EXPRESSION IN THE BRAIN | Non-Final OA | William Marsh Rice University |
| 18683081 | COMPOSITIONS AND METHODS FOR CONTROLLING ADAPTIVE IMMUNITY IN BACTERIA | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18001643 | METHODS OF IMPROVING PROTEIN EXPRESSION | Non-Final OA | ASTRAZENECA AB |
| 18761504 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18577377 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17283995 | VIRALLY EXPRESSED INHIBITORS OF PDZ DOMAINS, SUCH AS PICK1 AND USES THEREOF | Non-Final OA | University of Copenhagen |
| 17494047 | COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLUX CONTROL USING SYNTHETIC METABOLIC VALVES | Non-Final OA | DUKE UNIVERSITY |
| 18686437 | Base Editing System for Achieving A-To-C and/or A-To-T Base Mutations and Use Thereof | Non-Final OA | EAST CHINA NORMAL UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy